» Articles » PMID: 39268134

Clinical Characteristics and Microbial Signatures in the Lower Airways of Diabetic and Nondiabetic Patients with Pneumonia

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2024 Sep 13
PMID 39268134
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The microbial signatures in diabetes with pneumonia and the risk factors of severe pneumonia (SP) in diabetic patients are not clear. Our study explored microbial signatures and the association between clinical characteristics and SP then constructed a risk model to find effective biomarkers for predicting pneumonia severity.

Methods: Our study was conducted among 273 patients with pneumonia diagnosed and treated in our hospital from January 2018 to May 2021. Bronchoalveolar lavage fluid (BALF) samples and clinical data were collected. Metagenomic sequencing was applied after extracting the DNA from samples. Appropriate statistical methods were used to compare the microbial signatures and clinical characteristics in patients with or without diabetes mellitus (DM).

Results: In total, sixty-one pneumonia patients with diabetes and 212 pneumonia patients without diabetes were included. Sixty-six differential microorganisms were found to be associated with SP in diabetic patients. Some microbes correlated with clinical indicators of SP. The prediction model for SP was established and the receiver operating characteristic (ROC) curve demonstrated its accuracy, with the sensitivity and specificity of 0.82 and 0.91, respectively.

Conclusions: Some microorganisms affect the severity of pneumonia. We identified the microbial signatures in the lower airways and the association between clinical characteristics and SP. The predictive model was more accurate in predicting SP by combining microbiological indicators and clinical characteristics, which might be beneficial to the early identification and management of patients with SP.

Citing Articles

A Review on Risk Factors, Traditional Diagnostic Techniques, and Biomarkers for Pneumonia Prognostication and Management in Diabetic Patients.

Anwar S, Alhumaydhi F, Rahmani A, Kumar V, Alrumaihi F Diseases. 2024; 12(12.

PMID: 39727640 PMC: 11726889. DOI: 10.3390/diseases12120310.

References
1.
Bobadilla-Del-Valle M, Leal-Vega F, Torres-Gonzalez P, Ordaz-Vazquez A, Garcia-Garcia M, Tovar-Vargas M . Mycobacterial Growth Inhibition Assay (MGIA) as a Host Directed Diagnostic Tool for the Evaluation of the Immune Response in Subjects Living With Type 2 Diabetes Mellitus. Front Cell Infect Microbiol. 2021; 11:640707. PMC: 8167894. DOI: 10.3389/fcimb.2021.640707. View

2.
Cheng S, Hou G, Liu Z, Lu Y, Liang S, Cang L . Risk prediction of in-hospital mortality among patients with type 2 diabetes mellitus and concomitant community-acquired pneumonia. Ann Palliat Med. 2020; 9(5):3313-3325. DOI: 10.21037/apm-20-1489. View

3.
Liu Y, Cao Q, Ma B . Pathogens distribution and drug resistance in patients with acute cerebral infarction complicated with diabetes and nosocomial pulmonary infection. BMC Infect Dis. 2019; 19(1):603. PMC: 6617900. DOI: 10.1186/s12879-019-4142-9. View

4.
Ehrlich S, Quesenberry Jr C, Van Den Eeden S, Shan J, Ferrara A . Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2009; 33(1):55-60. PMC: 2797986. DOI: 10.2337/dc09-0880. View

5.
Wingrove J, Discipio R, Chen Z, Potempa J, Travis J, Hugli T . Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem. 1992; 267(26):18902-7. View